Estimated coefficients from the SARIMA model of new COVID-19 cases, assuming an abrupt effect following the implementation of two ETSs and one executive order in Oregon. by Raul Cruz-Cano (3751321)

Subjects:

Trends in COVID-19 cases in Oregon, for both the overall population and by agricultural worker type, between March 1, 2020 and February 27, 2021. by Raul Cruz-Cano (3751321)

Subjects:

Estimated number of COVID-19 cases and deaths among various types of agricultural workers in Oregon from March 1, 2020, to February 27, 2021. by Raul Cruz-Cano (3751321)

Subjects:

The results of linear mixed model. by Soheila Qanbari (20455173)

Subjects:

The flow of the participants from enrollment to analysis. by Soheila Qanbari (20455173)

Subjects:

Correlation between treatment-induced changes in lumbar motor control and N150 amplitude. by Soheila Qanbari (20455173)

Subjects:

Sensory-evoked potentials of N80 and N150. by Soheila Qanbari (20455173)

Subjects:

The mean and standard deviation of outcome measures. by Soheila Qanbari (20455173)

Subjects:

Linear relationships (Spearman’s r (p-value)) the treatment-induced changes in clinical and neurophysiological data. by Soheila Qanbari (20455173)

Subjects:

The demographical and clinical characteristics of subjects at baseline. by Soheila Qanbari (20455173)

Subjects:

Electrode montage and electric field distribution simulated with SimNIBS software. by Soheila Qanbari (20455173)

Subjects:

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Association of BMI with primary and secondary outcomes after adjusting for age, sex, index of multiple deprivation (for the United Kingdom data), primary surgical indication and Am... by Epaminondas Markos Valsamis (8194083)

Subjects:

BMI distribution of study population using World Health Organisation (WHO) categories. by Epaminondas Markos Valsamis (8194083)

Subjects:

Association of BMI with primary and secondary outcomes after adjusting for age, sex, index of multiple deprivation (for the United Kingdom data), primary surgical indication and Am... by Epaminondas Markos Valsamis (8194083)

Subjects:

Patient demographics by BMI missingness in the United Kingdom NJR data and Danish data. by Epaminondas Markos Valsamis (8194083)

Subjects:

Image 4_Pediatric kidney transplant recipients are at an increased risk for dysbiosis.jpeg by Gizem Yılmaz (20641691)

“…In addition, KTx recipients with a history of frequent urinary tract infections, diarrhea and reduced GFR showed significant increases in bacterial abundance (p < 0.05 for all).…”

Image 1_Pediatric kidney transplant recipients are at an increased risk for dysbiosis.jpeg by Gizem Yılmaz (20641691)

“…In addition, KTx recipients with a history of frequent urinary tract infections, diarrhea and reduced GFR showed significant increases in bacterial abundance (p < 0.05 for all).…”